(Q39409268)

English

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

scientific article published on June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mariola Fotin-Mleczek

1

object named as

Mariola Fotin-Mleczek

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Karl-Josef Kallen

7

object named as

Karl-Josef Kallen

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Regina Heidenreich

3

object named as

Regina Heidenreich

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Kai Zanzinger

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Christina Lorenz

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andreas Thess

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Katharina M Duchardt

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

1 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Journal of Gene Medicine

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

428-439

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

DNA vaccination in oncology: current status, opportunities and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Adoptive immunotherapy for cancer: building on success

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Signaling through OX40 enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Immune infiltration in human cancer: prognostic significance and disease control

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Tumor immunosurveillance in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Molecular mechanisms of natural killer cell activation.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Activation of NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Cytokines in cancer pathogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Close encounters of different kinds: dendritic cells and NK cells take centre stage

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

The bidirectional crosstalk between human dendritic cells and natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Allelic exclusion of Ly49-family genes encoding class I MHC-specific receptors on NK cells.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

In search of the 'missing self': MHC molecules and NK cell recognition

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Cancer treatment: the combination of vaccination with other therapies

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Combined modality immunotherapy and chemotherapy: a new perspective

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Combining Vaccines with Conventional Therapies for Cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Docetaxel in non-small cell lung cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Chemotherapy for recurrent and metastatic cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs).

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Coordination of intratumoral immune reaction and human colorectal cancer recurrence.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Effector memory T cells, early metastasis, and survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FJGM.2605

21 January 2018

Identifiers

10.1002/JGM.2605

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39409268&oldid=1826332705"